# Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

> **NCT01658501** · PHASE2 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 593 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** 50 mg PB1023
- **DRUG:** 70 mg PB1023
- **DRUG:** 100 mg PB1023
- **DRUG:** Placebo (0.9% Sodium Chloride)
- **DRUG:** Victoza®
- **OTHER:** Diet and Exercise
- **DRUG:** Metformin
- **DRUG:** Sulfonylurea
- **DRUG:** Metformin and Sulfonylurea

## Key facts

- **NCT ID:** NCT01658501
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 593 (ACTUAL)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658501, "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01658501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*